CASI Pharmaceuticals Begins Trading on OTCQB
Summary
CASI Pharmaceuticals announced its ordinary shares have commenced trading on the OTCQB, a move that typically signals a downgrade in listing status and can impact investor accessibility and liquidity.
Key Events · Corporate Governance and Compliance · CASI
-
Trading Venue Change
CASI Pharmaceuticals, Inc. announced its ordinary shares began trading on the OTCQB under the ticker CASIF on April 14, 2026.
-
Implications for Investors
A move to the OTCQB often indicates a company no longer meets the listing standards of a major exchange, potentially leading to reduced visibility, lower liquidity, and less institutional interest.
Analysis · CASI · Life Sciences
CASI Pharmaceuticals' move to trading on the OTCQB from a potentially higher exchange (implied by the move *to* OTCQB) is a significant event for a micro-cap company. This change typically results from not meeting the listing requirements of a major exchange, which can negatively impact investor perception, reduce liquidity, and limit institutional investment. While it ensures continued public trading, it generally signals a downgrade in market accessibility and company standing, making it harder to raise capital and attract new investors.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CASI was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.